US Supreme Court tells Federal Circuit Court: Rethink Teva decision

Supreme Court rules for Israel’s Teva generic drug manufacturer over multiple sclerosis drug patent.


WASHINGTON – The US Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review.

Israel’s Teva’s factory in Hungary – Photo: Bloomberg

On a 7-2 vote, the justices said that the US Court of Appeals for the Federal Circuit had not used the correct approach in analyzing whether the patent in question, due to expire in September 2015, was valid.


View original The Jerusalem Post publication at: